Impairments of the protein C system and fibrinolysis in infection- associated stroke

Stroke

Volumn 27, Issue 11, 1996, Pages 2005-2011

  Macko, Richard F ^a   Ameriso, Sebastian F ^a   Gruber, Andras ^b   Griffin, John H ^b   Fernandez, Jose A ^b   Barndt, Robert ^a   Quismorio Jr , Francisco P ^a   Weiner, John M ^a   Fisher, Mark ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

blood coagulation; blood proteins; cerebral infarction; fibrinolysis; infection

Indexed keywords

ACTIVATED PROTEIN C; COMPLEMENT COMPONENT C4B; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; ENCEPHALITIS; FIBRINOLYSIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RISK ASSESSMENT; RISK FACTOR; STROKE;

EID: 0029849589     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.11.2005     Document Type: Article

References (59)

1. Hindfelt B, Nilsson O. Brain infarction in young adults with particular reference to pathogenesis. Acta Neurol Scand. 1977;55:145-157.
2. Syrjanen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischemic brain infarction in young and middle aged patients. Br Med J. 1988;296:1156-1160.
3. Ameriso SF, Wong VLY, Quismorio FP, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction. Stroke. 1991;22:1004-1009.
4. Grau A, Buggle F, Heindl S, Steichen-Wiehn C, Banarjee T, Maiwald M, Rohlfs M, Suhr H, Fiehn W, Becher H, Hacke W. Recent infection as a risk factor for cerebrovascular ischemia. Stroke. 1995;26:373-379.
5. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet. 1994;343:435-439.
6. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ. Cytokine activation of vascular endothelium: effects on tissue type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem. 1988;263:5797-5803.
7. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989;73: 159-165.
8. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. J Biol Chem. 1989;264:20705-20713.
9. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989;320:1165-1172.
10. Hesselvik JF, Malm J, Dahlback B, Blomback M. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost. 1991;65:126-129.
11. Heeb MJ, Mosher D, Griffin JH. Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation. Blood. 1989;73:455-461.
12. Sacco RL, Owen J, Mohr JP, Tatemichi TK, Grossman BA. Free protein S deficiency: a possible association with cerebrovascular occlusion. Stroke. 1989;20:1657-1661.
13. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
14. Martinez HR, Rangel Guerra RA, Marfil LJ. Ischemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults. Stroke. 1993;24:19-25.
15. Fisher M, Francis R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity. Arch Neurol. 1990;47:1075-1079.
16. Macko RF, Ameriso SF, Barndt R, Clough W, Weiner JM, Fisher M. Precipitants of brain infarction: roles of preceding infection/inflammation and recent psychological stress. Stroke 1996;27:1999-2004.
17. Dyken M, Wolf P, Barnett HJM, Bergan J, Hass W, Kannel W, Kuller L, Kurtzke J, Sundt T. Risk factors in stroke: a statement for physicians by the Subcommittee on Risk Factors and Stroke of the Stroke Council. Stroke. 1984;15:1105-1111.
18. Grimaudo V, Hauert J, Bachmann F, Kruithof EKO. Diurnal variation of the fibrinolytic system. Thromb Haemost. 1989;62:495-499.
19. Wiman B, Mellbring G, Ranby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta. 1983;127:279-288.
20. Falkon L, Gari IM, Borrel M, Fontcuberta J. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis. Blood Coagul Fibrinol. 1992;3:33-38.
21. Chandler WL, Schmer G, Stratton JR. Optimum conditions for the stabilization and measurement of tissue plasminogen activator activity in human plasma. J Lab Clin Med. 1989;113:362-371.
22. Sprengers ED, Akkerman JWN, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost. 1986;55:325-329.
23. Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. Studies of human platelet alpha granule release in vivo. Blood. 1981; 58:607-618.
24. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood. 1992;79:2340-2348.
25. Griffin JH, Gruber A, Fernandez JA. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood. 1992;79:3203-3211.
26. Francis CW, Marder VJ. A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Hemost. 1982;8:25-35.
27. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment F1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991;65:153-159.
28. Stimmler M, Quismorio F, McGehee W, Boylen T, Sharma O. Anticardiolipin antibodies in acquired immunodeficiency syndrome. Arch Intern Med. 1989;149:1833-1835.
29. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4th April 1986. Clin Exp Immunol. 1987;68:215-222.
30. Broze GJ, Miletich JP. Biochemistry and physiology of protein C, protein S, and thrombomodulin. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: Lippincott Co; 1994:259-241.
31. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb Vasc Biol. 1992;12:135-145.
32. D'Angelo A, Landi G, D'Angelo SV, Orazio EN, Boccardi E, Candelise L, Mannucci PM. Protein C in acute stroke. Stroke. 1988;19:579-583.
33. Camerlingo M, Finazzi G, Casto L, Laffranchi C, Barbui T, Mamoli A. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology. 1991;41:1371-1373.
34. Anzola GP, Magoni M, Ascari E, Maffi V. Early prognostic factors in ischemic stroke: the role of protein C and protein S. Stroke. 1993;24:1496-1500.
35. Esmon CT, Taylor FB, Snow TR. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost. 1991;66:160-165.
36. Taylor FB, Chang A, Esmon CT, D'Angelo A, D'Angelo SV, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918-925.
37. Levine SR, Welch KMA. Antiphospholipid antibodies. Ann Neurol. 1989;26:386-389.
38. Antiphospholipid Antibodies in Stroke Study Group (APASS). Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993;43:2069-2073.
39. Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf, Caen J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells: inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost. 1988;60:54-58.
40. Vaarala O, Palosuo T, Kleemola M, Kimmo A. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986;41:8-15.
41. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood. 1989;74:2426-2432.
42. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest. 1995;95:309-316.
43. Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle aged women with stroke. Neurology. 1992;42:1029-1033.
44. Dahlback B. Inhibition of the protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem. 1986;261:12022-12027.
45. Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood. 1986;67:504-508.
46. Taylor FB, Chang A, Ferrell G, Mather T, Catlett R, Blick KE, Esmon CT. C4b-binding protein exacerbates the host response to Escherichia coli. Blood. 1991;78:357-363.
47. Boerger LM, Morris GR, Thurnau GR, Esmon CT, Comp PC. Oral contraceptives and gender affect protein S status. Blood. 1987;69:692-694.
48. Garcia de Frutos P, Alim RI, Hardig Y, Zoller B, Dahlback B. Differential regulation of α and β chains of C4b-binding protein during acute phase response resulting in stable plasma levels of free anticoagulant protein S. Blood. 1994;84:815-822.
49. Fletcher AP, Alkjaersig N, Davies A, Lewis M, Brooks J, Hardin W, Landeau W, Raichle ME. Blood coagulation and plasma fibrinolytic system pathophysiology in stroke. Stroke. 1976;7:337-348.
50. Feinberg WM, Bruck DC, Jeter MA, Corrigan JJ. Fibrinolysis after acute ischemic stroke. Thromb Res. 1991;64:117-127.
51. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 level on the molar concentration of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood. 1990; 76:930-937.
52. van Deventer SJH, Buller HR, Cate JWT, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76:2520-2526.
53. Voss R, Borkowski G, Reitz D. Activation and inhibition of fibrinolysis in septic patients in an intensive care unit. Br J Haematol. 1990;75:99-105.
54. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol. 1994;153:3664-3672.
55. Murakami K, Okajimi K, Uchibi M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996;87:642-647.
56. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH, Salem HH. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation. 1995;60:1525-1532.
57. Koh SCL, Yuen R, Veigas OAC. Plasminogen activators t-PA, u-PA, and its inhibitor (PAI) in normal males and females. Thromb Haemost. 1991;66:581-585.
58. Hallenbeck JM, Dutka AJ, Kochanek PM, Siren A, Pezeshkpour GH, Feuerstein G. Stroke risk factors prepare rat brainstem tissues for modified local Shwartzman reaction. Stroke. 1988;19: 863-869.
59. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor gene. Diabetes. 1995;44:37-42.